Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Trial Profile

A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belantamab mafodotin (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms DREAMM-1
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 13 Dec 2022 Results exploring whether complete target loss and/or immune impairment were observed in patients who received belamaf in the DREAMM-1 and -2 trials presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 18 Mar 2022 Results assessing to build an integrated time-course model of drug exposure, efficacy, and corneal events for future use in designing clinical studies (DREAMM-1 (NCT02064387) and DREAMM-2 (NCT03525678)), presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 01 Oct 2021 Results assessing efficacy outcomes for Idecabtagene vicleucel versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma from phase 2 KarMMa (14 January 2020 data cutoff), STORM part 1 (phase 2) and STORM part 2 (phase 2), DREAMM-1 (phase 1) and DREAMM-2 (phase 2) trials, published in the Leukemia and Lymphoma.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top